Due to activating mutations in PIK3CA and AKT1, and loss-of-function mutations in the tumor suppressor PTEN, it is frequently hyperactivated in triple-negative breast cancer, making this subtype of breast cancer particularly aggressive and resistant to conventional therapies. This evidence concerns the gene AKT1 and breast cancer.